je.st
news
Tag: gsks
FDA approves GSK's drug Nucala for severe asthma
2015-11-05 01:47:14| Biotech - Topix.net
GlaxoSmithKline Plc won U.S. regulatory approval for its drug Nucala to treat severe asthma, the Food and Drug Administration said on Wednesday. The drug, Nucala, known also as mepolizumab, was approved for use in combination with other therapies for patients 12 and older who have a history of severe asthma attacks.
Analysis of GSK's Seroxat antidepressant finds key data was held back
2015-09-17 12:07:34| Biotech - Topix.net
A medical journal criticized British drugmaker GlaxoSmithKline on Thursday for delaying access to key data from a trial of its antidepressant Seroxat that would have shown earlier that it is neither safe or effective in adolescents. The widely used medicine, known generically as paroxetine, is linked to an increased risk of suicide in young people and has carried a Food and Drug Administration "black box warning" advising against its use in adolescents since 2004.
Manufacturing Deal Wins China Cheap Supply Of GSK's New HIV Drug
2015-07-02 17:16:32| Biotech - Topix.net
China will receive cut-price supplies of GlaxoSmithKline's new HIV drug Tivicay, following a deal for Shanghai-based Desano Pharmaceuticals to become an additional manufacturer of the medicine's active ingredient. The collaboration between GSK's HIV unit ViiV Healthcare and Desano marks an improvement in the business climate for the British drugmaker, which was fined a record 3 billion yuan in September for bribing Chinese doctors.
GSK's new chairman Hampton to take charge in May
2015-02-26 19:12:05| Biotech - Topix.net
GlaxoSmithKline said on Thursday that its chairman-designate Philip Hampton would take charge of Britain's biggest drugmaker from May 7, marking an earlier transition than initially anticipated. Hampton, who chairs Royal Bank of Scotland, was named as the pharmaceutical company's next chairman last September, but GSK said at the time he might not take up the position until Sept.
Tags: may
charge
chairman
hampton
Exclusive- India's Lupin, U.S. firms weigh bids for GSK's mature drugs: sources
2014-07-22 22:02:47| Biotech - Topix.net
Assuming a multiple of between two and three times those sales, the assets on the block could fetch between $3.5 billion and $5.0 billion , the sources said.
Tags: sources
exclusive
drugs
firms